Thermo Fisher Scientific has opened a U.S. flagship bioprocess design center in Plainville, Massachusetts, adding new laboratory and training space for biologics developers working to move therapies from process development toward production.
The company announced the opening on April 28. The new center is located at Thermo Fisher’s Plainville site and gives customers access to company scientists, engineers, and bioproduction technologies in a hands-on collaboration setting. The goal is practical: test ideas earlier, troubleshoot process problems faster, and reduce the risk that often appears when biologics move from lab work to larger-scale manufacturing.
The new Bioprocess Design Center includes 4,000 square feet of laboratory and training space. According to Thermo Fisher, customers can work with integrated bioproduction solutions covering media, cell line development, single-use systems, chromatography, filtration, purification, and analytics. Those workflow areas are central to biologics development, including vaccines and cell and gene therapies.
For process engineers and laboratory teams, the value sits in early decision-making. Biologics production can become costly when a process fails late in development. By testing process steps, comparing options, and collecting data sooner, manufacturers can make better calls before committing to larger batches, new equipment, or commercial production plans.
The center also expands bioprocessing capabilities within Thermo Fisher’s 290,000-square-foot Plainville facility. That location places process development, technical consulting, and manufacturing services closer together, which may help teams move from troubleshooting to implementation with fewer handoffs.
This type of investment reflects a broader shift in life sciences manufacturing. Developers are under pressure to shorten timelines, control risk, and build more reliable production methods without sacrificing quality. That takes more than equipment. It requires trained people, documented processes, scalable workflows, and clear data from controlled lab environments.
As biologics pipelines grow more complex, facilities that bring process testing and production planning together may play a larger role in reducing scale-up delays. For manufacturers, the lesson is straightforward: strong lab work at the front end can protect quality, time, and cost later in the production cycle.
Article and Image Source: Thermo Fisher Scientific — April 28, 2026
